ESR1-Driven Resistance to CDK4/6 Inhibitors in Breast Cancer Thwarted by SERDs
MedPage Today,
Oncology/Hematology > Breast Cancer Time to next treatment reduced in mutant tumors with CDK4/6 inhibitor plus aromatase…
Oncology/Hematology > Breast Cancer Time to next treatment reduced in mutant tumors with CDK4/6 inhibitor plus aromatase…
By Clinical Content Hub The global disease burden of breast cancer (BC) is a serious health concern worldwide, especially among…
A new hormonal therapy is now available for people with treatment-resistant advanced or metastatic breast cancer.
ESR1 mutations, a known driver of resistance to standard endocrine therapy, are present in up to 40% of ER+, HER2- advanced…